Abstract

The amyloid beta peptides (Abeta) are the major components of the senile plaques characteristic of Alzheimer's disease. Abeta peptides are generated from the cleavage of amyloid precursor protein (APP) by beta- and gamma-secretases. Beta-secretase (BACE), a type-I transmembrane aspartyl protease, cleaves APP first to generate a 99-amino acid membrane-associated fragment (CT99) containing the N terminus of Abeta peptides. Gamma-secretase, a multi-protein complex, then cleaves within the transmembrane region of CT99 to generate the C termini of Abeta peptides. The production of Abeta peptides is, therefore, dependent on the activities of both BACE and gamma-secretase. The cleavage of APP by BACE is believed to be a prerequisite for gamma-secretase-mediated processing. In the present study, we provide evidence both in vitro and in cells that BACE-mediated cleavage between amino acid residues 34 and 35 (Abeta-34 site) in the Abeta region is dependent on gamma-secretase activity. In vitro, the Abeta-34 site is processed specifically by BACE1 and BACE2, but not by cathepsin D, a closely related aspartyl protease. Moreover, the cleavage of the Abeta-34 site by BACE1 or BACE2 occurred only when Abeta 1- 40 peptide, a gamma-secretase cleavage product, was used as substrate, not the non-cleaved CT99. In cells, overexpression of BACE1 or BACE2 dramatically increased the production of the Abeta 1-34 species. More importantly, the cellular production of Abeta 1-34 species induced by overexpression of BACE1 or BACE2 was blocked by a number of known gamma-secretase inhibitors in a concentration-dependent manner. These gamma-secretase inhibitors had no effect on enzymatic activity of BACE1 or BACE2 in vitro. Our data thus suggest that gamma-secretase cleavage of CT99 is a prerequisite for BACE-mediated processing at Abeta-34 site. Therefore, BACE and gamma-secretase activity can be mutually dependent.

Highlights

  • Amyloid ␤ (A␤)1 peptides are principal components of the neuritic plaques that represent one of the hallmarks of AD

  • The cellular production of A␤ 1–34 species induced by overexpression of BACE1 or BACE2 was blocked by a number of known ␥-secretase inhibitors in a concentration-dependent manner

  • The cellular production of A␤ 1–34 species induced by overexpression of BACE1 or BACE2 was blocked by known ␥-secretase inhibitors in a concentration-dependent manner, whereas the ␥-secretase inhibitors had no effect on enzymatic activity of BACE1 or BACE2 in vitro

Read more

Summary

The abbreviations used are

A␤, ␤ amyloid peptide; AD, Alzheimer’s disease; BACE, ␤ site APP-cleaving enzyme; APP, amyloid precursor protein; CT99, C-terminal; HEK, human embryonic kidney; MALDI, matrix-assisted laser desorption/ionization; SELDI, surface-enhanced pathology. Production of A␤ peptides is initiated first by activities of BACE1, which cleaves APP at the ␤ site to yield a membrane-associated APP C-terminal fragment of 99 amino acid residues (CT99) [1,2,3,4,5,6]. We found that BACE-mediated cleavage at the A␤-34 site is dependent on the ␥-secretase activity. BACE cleaves the A␤-34 site in vitro only within A␤ 1– 40 peptide, a product from ␥-secretase, not the site in the noncleaved CT99 fragment. Our results suggest that the cleavage activity of BACE at the A␤-34 site, both in vitro and in cells, is dependent on ␥-secretase activity. BACE and ␥-secretase activity can be mutually dependent

MATERIALS AND METHODS
RESULTS
DISCUSSION
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.